An observational study in Epilepsy and Encephalitis Autoimmune, sponsored by Shen Chun-Hong. Recruiting at 1 site in China. Open to participants aged 14 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Shen Chun-Hong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.
Among the 101 studies in Epilepsy with a site in China, this one is the 17th largest by planned enrollment of the 37 observational ones that give a count, is one of 8 that started in 2023, is one of 37 observational ones, reaches primary completion later than 16 of the 40 other live ones, and was the 72nd registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in China
Ages 18–65
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 18–75
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 18+ · Women only · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 14 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 23 · Phase 4 5
First in 2006; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 107 across 541 observational studies indexed under Epilepsy.
Median enrollment 141 across the 64 interventional studies, 234 across the 37 observational. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 101 have an industry lead sponsor. The 10 most frequent:
Shen Chun-Hong is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Shen Chun-Hong has 2 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
14 of the studies in Epilepsy with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT07095933Xuanwu Hospital, BeijingThe Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy | 2026-12-01 |
| NCT03822741Children's Hospital of Fudan UniversityEtiology and Treatment of Neonatal Seizure | 2026-12-30 |
| NCT04917939Second Affiliated Hospital, School of Medicine, Zhejiang UniversityGene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 101 studies in Epilepsy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.
It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.
Patients who have new-onset focal seizure with unknown etiology; and focal seizure is considered according to the seizure seiology, electroencephalography findings and/or other relevant information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Detectable serum neural autoantibodies
such as NMDAR、AMPAR1、AMPAR2、LGI1、lg LON5、DPPX、GAD65、mGluR5、MOG
Time frame: at baseline
Neuronal surface antibodies-mediated autoimmune- encephalitis
diagnosed according to the 2016 diagnostic criteria
Time frame: at baseline
The proportion of seizure freedom
We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition
Time frame: through study completion, an average of 1 year
The proportion of drug-resistent epilepsy
We defined drug-resistent epilepsy according to the International League Against Epilepsy (ILAE) definition
Time frame: through study completion, an average of 1 year
Clinical severity and recovery
modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.
Of 193 non-industry observational studies under Epilepsy, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 179. This study's planned 40 months is below that.
Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 24 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.